Last updated September 9, 2026
Key finding
Patients who received FMT reduced their median Gastrointestinal Symptom Rating Scale—IBS score from 58 (IQR 54–65) to 35 (32–48).
This randomized pilot trial evaluated the effects of fecal microbiota transplantation (FMT) in patients with type 1 diabetes and gastroenteropathy, finding significant improvements in gastrointestinal symptoms.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This randomized pilot trial evaluated the effects of fecal microbiota transplantation (FMT) in patients with type 1 diabetes and gastroenteropathy, finding significant improvements in gastrointestinal symptoms.
This study highlights the potential of fecal microbiota transplantation as a therapeutic option for patients with type 1 diabetes experiencing gastrointestinal complications. Given the chronic nature of diabetes and its impact on quality of life, effective management of gastrointestinal symptoms is crucial for improving overall patient well-being.
Small sample size limits generalizability. Short duration may not capture long-term effects. Lack of blinding in outcome assessment could introduce bias.
Published in
Publication details and source links for this paper.
Katrine LH, Simon MDB, Ditte SK, et al. Faecal microbiota transplantation for patients with type 1 diabetes and gastroenteropathy: a randomized pilot trial. eClinicalMedicine. 2025;79:103000. doi:10.1016/j.eclinm.2024.103000
FMT reduced the median Gastrointestinal Symptom Rating Scale—IBS score by 23 points (p=0.01).
The Irritable Bowel Syndrome Impact Scale score improved by 32 points (p=0.02) with FMT.
The Patient Assessment of Gastrointestinal Symptom Severity Index declined by 17 points (p=0.03) after FMT.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Healthy lean-donor fecal microbiota transplantation capsules and Gastrointestinal disorders incidence, Irritable Bowel Syndrome Impact Scale score, Patient Assessment of Gastrointestinal Symptom Severity Index.
This study contributes evidence to
Primary intervention
Healthy lean-donor fecal microbiota transplantation capsules
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
3
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Healthy lean-donor fecal microbiota transplantation capsules → Gastrointestinal disorders incidence
Healthy lean-donor fecal microbiota transplantation capsules → Gastrointestinal disorders incidence
Healthy lean-donor fecal microbiota transplantation capsules → Irritable Bowel Syndrome Impact Scale score
Healthy lean-donor fecal microbiota transplantation capsules → Irritable Bowel Syndrome Impact Scale score
Healthy lean-donor fecal microbiota transplantation capsules → Patient Assessment of Gastrointestinal Symptom Severity Index
Healthy lean-donor fecal microbiota transplantation capsules → Patient Assessment of Gastrointestinal Symptom Severity Index
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Healthy lean-donor fecal microbiota transplantation capsules and Gastrointestinal Adverse Events, Healthy lean-donor fecal microbiota transplantation capsules and Irritable Bowel Syndrome Impact Scale score.
This study contributes to the evidence on the following intervention-outcome relationships.
Procedures
Curated evidence collections and hubs this study is part of.
All studies measuring Gastrointestinal Adverse Events
Measures Gastrointestinal Adverse Events as a key outcome.
All studies on Healthy lean-donor fecal microbiota transplantation capsules
Contributes to Healthy lean-donor fecal microbiota transplantation capsules evidence base.
All studies measuring Irritable Bowel Syndrome Impact Scale score
Measures Irritable Bowel Syndrome Impact Scale score as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Healthy lean-donor fecal microbiota transplantation capsules appears to improve irritable bowel syndrome impact scale score.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Irritable Bowel Syndrome Impact Scale score
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Healthy lean-donor fecal microbiota transplantation capsules appears to improve patient assessment of gastrointestinal symptom severity index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Patient Assessment of Gastrointestinal Symptom Severity Index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear reduction in gastrointestinal disorders incidence with Healthy lean-donor fecal microbiota transplantation capsules.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Gastrointestinal disorders incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
